Vitruvias Recalls Thyroid Tablets 30 mg Lot Over Superpotency

A confirmed superpotency finding in a narrow therapeutic index drug has prompted Vitruvias Therapeutics, Inc. to voluntarily recall one lot of Thyroid Tablets, USP 30 mg to the consumer level, a scenario that places finished-product release controls and out-of-specification investigation protocols directly under scrutiny for QA teams managing similar solid oral dosage forms.

The recall covers Lot No. 504950 (NDC 69680-166-00), expiring September 30, 2026, with 1,955 units sold from a released quantity of 3,655. Distribution ran nationwide to direct accounts from January 31, 2025 through September 30, 2025. Testing confirmed the potential for superpotency; no adverse events have been reported to the company to date.

The clinical risk profile for this product class is not trivial. Thyroid, USP is a porcine-derived combination of levothyroxine and liothyronine used to treat hypothyroidism. Superpotent dosing can precipitate hyperthyroidism, with sequelae including hypertension, cardiac arrhythmia, and tachycardia. Elevated risk populations include elderly patients, pregnant women, and infants, groups where excess thyroid hormone exposure carries documented associations with cardiac adverse outcomes, premature delivery, low birth weight, and developmental effects. The narrow therapeutic window makes even modest potency excursions clinically significant.

For plant heads and QA directors, the lot disposition data warrants attention: nearly half the released units remain unaccounted for at the consumer level, underscoring the operational complexity of consumer-level recalls for oral solid products distributed through wholesale channels. Vitruvias is notifying wholesalers by email and phone to halt distribution and is arranging destruction of recalled product. Patients currently taking Lot 504950 are advised not to discontinue use without consulting a healthcare provider, consistent with standard guidance for thyroid replacement therapy.

Read against 21 CFR Part 211 finished-product testing requirements and ICH Q10 quality system expectations, a confirmed superpotency result reaching distribution signals a potential gap somewhere in the release-testing or stability oversight chain, whether in assay methodology, sampling, or lot disposition decision-making. QA leads reviewing their own OOS investigation procedures for narrow therapeutic index products should benchmark the Vitruvias case against their current CAPA documentation and escalation thresholds.

The recall is being conducted with FDA knowledge; adverse events may be reported through the agency's MedWatch program. Consumers may contact Vitruvias at [email protected] or (256) 239-9373, Monday through Friday, 9 a.m. to 5 p.m. CT.

The proportion of the 1,955 sold units recovered through the recall process will serve as a measurable indicator of the effectiveness of Vitruvias's consumer-level notification and retrieval strategy.

Source: U.S. Food and Drug Administration recalls database via FDA.gov RSS Feed, August 24, 2026. Company announcement dated August 21, 2026.